Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada.
Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
J Pharmacol Exp Ther. 2022 Sep;382(3):335-345. doi: 10.1124/jpet.122.001155. Epub 2022 Jul 7.
6-Mercaptopurine (6-MP) is used extensively in the treatment of acute lymphoblastic leukemia (ALL) and inflammatory bowel diseases. Our laboratory determined previously, using a recombinant HEK293 cell model, that the -encoded equilibrative nucleobase transporter 1 (ENBT1) transports 6-MP into cells and significantly impacts the cytotoxicity of 6-MP in that model. To further investigate the clinical relevance of this finding, we now extend this work to an analysis of the impact of /ENBT1 expression and function on 6-MP uptake and cytotoxicity in leukemic lymphoblasts, the therapeutic target of 6-MP in ALL. A panel of ALL cell lines was assessed for /ENBT1 expression, ENBT1 function, and sensitivity to 6-MP. There was a significant difference in expression among the cell lines that positively correlated with the rate of ENBT1-mediated 6-MP uptake. Cells with the lowest expression of (SUP-B15: V = 22± 5 pmol/µl per second) were also significantly less sensitive to 6-MP-induced cytotoxicity than were the highest expressing cells (ALL-1: V = 69 ± 10 pmol/µl per second). Furthermore, knockdown of ENBT1 using short hairpin RNA interference (shRNAi) in RS4;11 cells caused a significant decrease in ENBT1-mediated 6-MP uptake (V: RS4;11 = 40 ± 4 pmol/µl per second; RS4;11 shRNAi = 26 ± 3 pmol/µl per Second) and 6-MP cytotoxicity (EC: RS4;11 = 0.58 ± 0.05 µM; RS4;11 shRNAi =1.44 ± 0.59 µM). This study showed that ENBT1 is a major contributor to 6-MP uptake in leukemia cell lines and may prove to be a biomarker for the therapeutic efficacy of 6-MP in patients with ALL. SIGNIFICANCE STATEMENT: This study shows that -encoded equilibrative nucleobase transporter 1 is responsible for the transport of 6-mercaptopurine (6-MP) into leukemia cells and that its level of expression can impact the cytotoxicity of 6-MP. Further studies are warranted to investigate the therapeutic implications in patient populations.
6-巯基嘌呤(6-MP)广泛用于治疗急性淋巴细胞白血病(ALL)和炎症性肠病。我们的实验室之前使用重组 HEK293 细胞模型确定,编码的摄取核苷转运蛋白 1(ENBT1)将 6-MP 转运到细胞内,并对该模型中 6-MP 的细胞毒性产生重大影响。为了进一步研究这一发现的临床相关性,我们现在将这项工作扩展到分析 /ENBT1 表达和功能对 ALL 中 6-MP 摄取和细胞毒性的影响,这是 6-MP 的治疗靶点。评估了一组 ALL 细胞系的 /ENBT1 表达、ENBT1 功能和对 6-MP 的敏感性。细胞系之间存在 /ENBT1 表达的显著差异,与 ENBT1 介导的 6-MP 摄取率呈正相关。表达最低的 (SUP-B15:V = 22±5 pmol/µl 每秒)的细胞对 6-MP 诱导的细胞毒性也明显低于表达最高的细胞(ALL-1:V = 69 ± 10 pmol/µl 每秒)。此外,使用短发夹 RNA 干扰(shRNAi)在 RS4;11 细胞中敲低 ENBT1 导致 ENBT1 介导的 6-MP 摄取(V:RS4;11 = 40 ± 4 pmol/µl 每秒;RS4;11 shRNAi = 26 ± 3 pmol/µl 每秒)和 6-MP 细胞毒性(EC:RS4;11 = 0.58 ± 0.05 µM;RS4;11 shRNAi = 1.44 ± 0.59 µM)显著降低。这项研究表明,ENBT1 是白血病细胞系中 6-MP 摄取的主要贡献者,并且可能成为 ALL 患者 6-MP 治疗疗效的生物标志物。意义声明:这项研究表明,-编码的摄取核苷转运蛋白 1 负责将 6-巯基嘌呤(6-MP)转运到白血病细胞中,其表达水平可以影响 6-MP 的细胞毒性。需要进一步研究以调查其在患者群体中的治疗意义。